The 2026 Global Delphi Consensus named protective and acne-linked Cutibacterium acnes strains, but care for persistent adult acne stays the same for now. Strain-specific treatments are not ready for routine use because standard drugs have stronger trial support.
C. acnes strains are subtypes of a common skin bacterium with different effects on pores. For adults with ongoing breakouts, the new strain map explains disease better than it treats disease.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Which strains are linked to acne or protection?
- What did the 2026 consensus agree on?
- Why has treatment not changed yet?
- What helps persistent adult acne now?
Which strains are linked to acne or protection?
Phylotypes IA-1, IA-2, IB-1, IB-2 and IC are tied to acne, while clade II is tied to healthy skin. Ribotypes RT4 and RT5 track with breakouts, and RT2 and RT6 track with clear skin, as recorded in Nature Communications the strain analysis. A phylotype is a genetic subgroup, and a ribotype is a finer RNA-based split.
Extracellular-vesicle work reported in Scientific Reports split the same pattern further. SLST type A1, from phylotype IA1, acted acne-prone. SLST types H1 and H2, from phylotype IB, acted as protective commensals with distinct protein cargo that affects inflammation and sebum pathways.
What did the 2026 consensus agree on?
The Global Delphi Consensus on Acne and the Microbiome was published in Pharmaceuticals in March 2026. It unanimously agreed microbiome-targeted treatments should be adopted for acne management, described in the 2026 consensus report. The panel also reached 89% agreement that the microbiome shapes severity, the gut-skin axis affects acne, and pre-, pro- and postbiotics hold therapeutic potential.
The consensus describes Staphylococcus epidermidis plus balanced C. acnes strains as supporting immune synergy. Together they help hold pH, sebum balance and barrier strength. A shift toward dysbiosis, or microbial imbalance, drives acne development.
Why has treatment not changed yet?
Current standard care still follows the 2024 American Academy of Dermatology guidelines. Those guidelines strongly recommend benzoyl peroxide, topical retinoids and topical or oral antibiotics including doxycycline, not strain-specific therapy, according to the Academy report in the academy's updated guidelines. A 2026 systemic-therapy review in Dermatology Times called probiotics, C.
acnes virulence-factor vaccines and strain replacement promising. It also flagged limits from strain variability, small controlled trials and scarce head-to-head data versus isotretinoin. Strain labels vary by person, so a protective strain in one study may not act the same in another patient.
What helps persistent adult acne now?
For persistent acne in adults, especially women, established systemic options have the strongest support. Spironolactone shows strong efficacy and can outperform doxycycline.
Combined oral contraceptives approach antibiotic efficacy by six months but carry thromboembolic risk, reported in the 2026 systemic-therapy review in Dermatology Times the 2026 systemic-therapy review. Use the next dermatology visit to match those options to prior treatment: Bring a six-month treatment timeline to that visit.
- list benzoyl peroxide, retinoid and antibiotic courses tried and response length
- ask whether spironolactone fits a persistent adult pattern
- ask about contraceptive benefit by six months versus clot risk
You Might Also Like
- The 2026 Global Delphi Consensus on Acne and the Microbiome: Why the Findings May Not Change Acne Care Yet for Adults With Persistent Acne
- Protective and Acne-Associated Microbial Strains in the 2026 Consensus: Safety and Skin-Reaction Questions for Adults With Persistent Acne
- Why the 2026 Probiotic and Secretome Paper Reports No Trial Results Yet: Why the Findings May Not Change Acne Care Yet for Adults With Persistent Acne